Navigation Links
Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments

Individuals with moderate to severe chest pains (angina) who have not found relief from medication may benefit from a new gene therapy approach being used by cardiologists at Rush University Medical Center to grow new blood vessels in the heart.

The phase II clinical research study uses vascular endothelial growth factor-2 (VEGF-2) in the form of a solution containing a DNA plasmid that is delivered using catheterization to heart tissue that has been damaged from insufficient blood flow.

Once the catheter reaches the targeted site inside of the heart, the VEGF-2 is injected into the heart muscle region with inadequate blood supply. The DNA plasmid is then taken up by the middle muscular layer of the heart wall near the injection site. Inside the cell, the DNA encoded VEGF-2 expresses itself which in turn stimulates the growth of new blood vessels by promoting the proliferation of endothelial cells in the heart.

New blood vessels are required to provide oxygen-carrying blood to heart muscles to compensate for the blocked heart arteries. The subsequent, improved blood flow relieves the painful symptoms of angina.

"The process of growing new blood vessels, or angiogenesis, should occur over the course of four to eight weeks following the procedure which is done in the cardiac catheterization lab at Rush," said Dr. Gary L. Schaer, the principal investigator of the trial at Rush and director of the Rush Cardiac Catheterization Labs. "The patient goes home the next day." Several patients have received the gene therapy and all are doing well.

Individuals who may be candidates for this gene therapy study trial must have moderate to severe angina, but cannot also be candidates for treatment using angioplasty or bypass surgery. Angioplasty involves a catheterization with a balloon-like device that opens blocked arteries, while bypass surgery requires open-heart surgery to place veins removed from the patient's leg or arteries taken from
'"/>

Source:Rush University Medical Center


Page: 1 2

Related biology news :

1. Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer
2. Researchers Closer To Helping Hearing-Impaired Using Stem Cells
3. Using nanoparticles, in vivo gene therapy activates brain stem cells
4. Using computers and DNA to count bacteria
5. Using the genomic shortcut to predict bacterial behavior
6. Using natures most primitive anti-viral defense system to find new approaches to cancer research
7. Using dental X-rays to detect osteoporosis
8. Using brain scans, researchers find evidence for a two-stage model of human perceptual learning
9. Using nanomagnets to enhance medical imaging
10. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
11. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
Post Your Comments:
(Date:10/18/2014)... genetic conditions, a certain type of exome sequencing method ... traditional molecular diagnostic methods, according to a study appearing ... to coincide with the American Society of Human Genetics ... region of the genome (the complete set of genes ... has been rapidly applied in research settings and recent ...
(Date:10/17/2014)... German . ... When treating overdoses, doctors are often limited to supportive therapy ... is a combination of drugs involved. So what can be ... grandmother,s pills? ETH professor Jean-Christophe Leroux from the Institute of ... to this question. "The task was to develop an agent ...
(Date:10/16/2014)... the bowel lining develops and, in the process, suggested ... The researchers produced evidence that stem cells are responsible ... feature of the bowel lining, and believe these stem ... finding as scientists are still divided on the stem ... Wee Tan and Professor Tony Burgess from the Walter ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Emergency aid for overdoses 2Emergency aid for overdoses 3Cryptic clues drive new theory of bowel cancer development 2
... (Garrison NY) A Hastings Center workshop examining moral issues ... J. Craig Venter Group announced that it had created ... biology certainly raises deep philosophical and moral questions about ... a Hastings Center scholar who is managing the project. ...
... polluting some of California,s most popular beaches. Yet few ... systems and coastal contamination. Now, in ... have tracked a plume of polluted groundwater from a ... beaches. The researchers say their findings could be an ...
... ancient frogs may soon be mined to extinction, if the ... for mining go ahead. The primitive Archey,s frog ( ... are two of the species that inhabit the area of ... mining is planned to take place. Archey,s frog is ...
Cached Biology News:Stanford scientists track polluted groundwater to the sea 2Stanford scientists track polluted groundwater to the sea 3Stanford scientists track polluted groundwater to the sea 4Prehistoric frogs face extinction 2
(Date:10/20/2014)... NEW YORK , Oct. 20, 2014 /PRNewswire/ ... of their experimental ZMapp™ antibody therapeutic to fight ... of how difficult and time-consuming the production of ... healthcare market research publisher said that while some ... cycle of this compound, those with industry knowledge ...
(Date:10/20/2014)... MENLO PARK, Calif. , Oct. 20, 2014 ... announced today that the Company has signed a ... Institute of Regenerative Medicine (CIRM), effective October 1, ... of Clinical Development payments and the release of ... $14.3 million CIRM grant award for clinical development ...
(Date:10/20/2014)... VIENNA , October 20, 2014 ... of gastrointestinal (GI) disorders and the delivery of care ... liver diseases and worrying inequalities in the provision of ... survey, which was commissioned by United European Gastroenterology (UEG), ... greater political and public awareness of the burden of ...
(Date:10/20/2014)... Oct. 20, 2014 PureTech , a ... big healthcare problems, announced today the closing of ... participation from Invesco Perpetual, a $120 Billion group ... drive PureTech,s existing pipeline forward and to advance ... the scientific creativity to really go for the ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... David Meyer to our team as the Vice President of ... the executive leadership in building upon the HumanTouch health strategy. ... (IT) experience and expertise HumanTouch has been cultivating for 15 ... more than 20 years of diverse experience in the health ...
... 2011 PharmAthene, Inc. (NYSE Amex: PIP ... the Russell Global Index and the Russell 3000 Index ... and global equity indexes on June 24, 2011.  The ... largest U.S. companies based on total market capitalization.  The ...
... 27, 2011 Chimerix, Inc., a pharmaceutical ... with the Biomedical Advanced Research and Development Authority (BARDA) ... Services (HHS) that will resolve the Government Accountability Office ... to SIGA Technologies, Inc. for the development and delivery ...
Cached Biology Technology:HumanTouch Welcomes David Meyer as Vice President of HumanTouch's new Health Solutions Division 2PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index 2PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index 3PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index 4Chimerix and BARDA Reach Agreement Ending GAO Review of Smallpox Antiviral Contract 2Chimerix and BARDA Reach Agreement Ending GAO Review of Smallpox Antiviral Contract 3Chimerix and BARDA Reach Agreement Ending GAO Review of Smallpox Antiviral Contract 4
... (GST) is commonly used as a fusion ... (1). The GSTTag sequence has been reported ... cases the solubility of its fusion partners. ... form, GSTTag fusion proteins can be purified ...
... The Bio-Stack is compatible with BioTeks ... Speed, ease of use and walkaway ... microplate process. When used with the ... dispenser, the Bio-Stacks small footprint fits ...
... for the use of small interfering RNA ... the RNA interference,(RNAi) pathway have generated tremendous ... fields. siRNA for experimental use can be,synthesized ... then transfected into the target cells in ...
... scientists who have access to microarray scanning and ... with proteins from S&Ss antibody menu or from ... performed by the customer. Its as easy as ... with an expert and define the best adapted ...
Biology Products: